Skip to content

KERYX BIOPHARMACEUTICALS INC: 10-Q filed 2015-10-29

What KERYX BIOPHARMACEUTICALS INC reported in its quarterly report filed 2015-10-29 (fiscal Q3 2015): 27 published measures, 70 facts as tagged in accession 0001193125-15-358194.

This filing

Form
10-Q (quarterly report)
Filed
2015-10-29
Fiscal period
fiscal Q3 2015
Accession
0001193125-15-358194 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All KERYX BIOPHARMACEUTICALS INC filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2015-09-30154,654,000USD
At 2014-12-31103,628,000USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2015-09-3033,584,000USD
At 2014-12-3130,144,000USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2015-09-30121,070,000USD
At 2014-12-3173,484,000USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2015-09-30102,208,000USD
At 2014-12-3174,284,000USD
At 2014-09-3084,132,000USD
At 2013-12-3155,696,000USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2015-07-01 to 2015-09-30-30,745,000USD92
2015-01-01 to 2015-09-30-85,361,000USD273
2014-07-01 to 2014-09-30-35,289,000USD92
2014-01-01 to 2014-09-30-71,233,000USD273

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2015-01-01 to 2015-09-30432,000USD273
2014-01-01 to 2014-09-301,199,000USD273

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2015-07-01 to 2015-09-304,208,000USD92
2015-01-01 to 2015-09-307,897,000USD273
2014-07-01 to 2014-09-30256,000USD92
2014-01-01 to 2014-09-3010,256,000USD273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2015-09-30-636,219,000USD
At 2014-12-31-550,858,000USD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2015-07-01 to 2015-09-3022,000USD92
2015-01-01 to 2015-09-3067,000USD273

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2015-09-302,604,000USD
At 2014-12-311,532,000USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2015-07-01 to 2015-09-304,575,000USD92
2015-01-01 to 2015-09-3012,950,000USD273
2014-07-01 to 2014-09-308,240,000USD92
2014-01-01 to 2014-09-3013,396,000USD273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2015-07-01 to 2015-09-30-30,823,000USD92
2015-01-01 to 2015-09-30-85,615,000USD273
2014-07-01 to 2014-09-30-35,398,000USD92
2014-01-01 to 2014-09-30-71,592,000USD273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2015-09-30147,743,000USD
At 2014-12-3198,596,000USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2015-09-3030,603,000USD
At 2014-12-3129,311,000USD

Goodwill carrying amount

Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.

PeriodValueUnitDays
At 2015-09-303,208,000USD
At 2014-12-313,208,000USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2015-09-302,628,000USD
At 2014-12-31834,000USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2015-07-01 to 2015-09-3035,031,000USD92
2015-01-01 to 2015-09-3093,512,000USD273
2014-07-01 to 2014-09-3035,654,000USD92
2014-01-01 to 2014-09-3081,848,000USD273

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2015-09-3036,705,000USD
At 2014-12-317,830,000USD

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

PeriodValueUnitDays
2015-07-01 to 2015-09-3020,205,000USD92
2015-01-01 to 2015-09-3059,847,000USD273
2014-07-01 to 2014-09-3016,447,000USD92
2014-01-01 to 2014-09-3036,007,000USD273

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2015-07-01 to 2015-09-3011,150,000USD92
2015-01-01 to 2015-09-3028,704,000USD273
2014-07-01 to 2014-09-3019,053,000USD92
2014-01-01 to 2014-09-3045,687,000USD273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2015-09-30105,225,545shares
At 2014-12-3192,678,841shares

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2015-09-301,099,000USD
At 2014-12-31292,000USD

Other noncurrent liabilities

Noncurrent liabilities the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2015-09-30647,000USD
At 2014-12-31133,000USD

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2015-07-01 to 2015-09-30100,000USD92
2015-01-01 to 2015-09-30321,000USD273
2014-07-01 to 2014-09-30109,000USD92
2014-01-01 to 2014-09-30359,000USD273

Deferred income tax expense or benefit

The deferred portion of income tax expense or benefit, arising from timing differences. It is not tax paid in the period.

PeriodValueUnitDays
2015-01-01 to 2015-09-3067,000USD273

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2015-01-01 to 2015-09-301,794,000USD273

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2015-01-01 to 2015-09-3027,519,000USD273
2014-01-01 to 2014-09-30912,000USD273

Inspect the source

Entity
KERYX BIOPHARMACEUTICALS INC / CIK 0001114220
Captured
SEC response SHA-256
7185e222dc2993abdd2db1f8a304a0548c5ebb488c75064e4ec3caabea49020d

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001114220.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))